Margin Width The Key To Control Of Ductal Carcinoma In Situ Of The Breast

May 13, 1999

USC New England Journal Of Medicine Study Urges Caution In Use Of Radiation Therapy

LOS ANGELES, May 5, 1999 - Patients with one of the most common and curable forms of breast cancer may be undergoing radiation therapy unnecessarily, according to a University of Southern California study to be published in the May 13 New England Journal of Medicine.

The study, headed by Melvin J. Silverstein, M.D., medical director of the Harold E. and Henrietta C. Lee Breast Center at the USC/Norris Comprehensive Cancer Center, examines ductal carcinoma in situ (DCIS), a noninvasive breast cancer that has been the subject of a recent heated debate over treatment. Until 1980, DCIS was a relatively uncommon disease, representing only about 1 percent of all newly diagnosed cases of breast cancer. During the past two decades - as mammography has become more widely used and technically better - the number of new cases has increased dramatically.

Today DCIS represents as much as 40 percent of new breast cancer cases diagnosed by mammography, and estimates suggest that approximately 40,000 new cases of DCIS will be diagnosed this year in the U.S. Seventy to 80 percent of these patients are eligible for breast preserving lumpectomy rather than mastectomy. But opinion is currently divided on whether radiation therapy is necessary for all DCIS patients who choose lumpectomy.

In the NEJM article, Silverstein, a surgical oncologist, and colleagues found that radiation therapy does not appear to benefit patients where the margin width - the distance between the boundary of the lesion and the edge of the excised specimen - is 10 millimeters or more.

"Wide margin width makes complete excision more likely," says Silverstein. "Since DCIS is a noninvasive cancer that does not spread (metastasize), complete excision should cure the patient. These findings will have important ramifications for thousands of women with the disease. These data suggest that radiation therapy may not be the best option for some subgroups of patients with DCIS who choose to preserve their breast."

These USC data, the result of an analysis of 469 patients choosing breast preservation, suggest that eradication of the cancer can be achieved when margin widths are sufficiently wide. For the purposes of the study, tumors were divided into three groups by margin width (determined by direct management or ocular micrometry): close or involved (less than 1 mm); intermediate (1 to less than 10 mm) and wide (10 mm or more).

"The fact that there were only three recurrences among 133 patients with 10 mm or greater margins makes it unlikely that radiation therapy could have any significant impact on this subgroup," says Silverstein.

When the margin widths are less than 10 mm, radiation therapy should remain a treatment option. The benefit of radiation therapy increases as the margin width decreases - so that patients in whom the margin width is less than 1 mm show the most significant benefit from postoperative radiation therapy. In the intermediate margin width subgroup (1 to less than 10 mm) there was an 8 percent reduction in local recurrence rate when postoperative radiation therapy was used, but the trend was not statistically significant, according to Silverstein.

Part of the controversy over treatment for DCIS stems from the fact that to date only one prospective randomized study has been published. This is protocol B-17, conducted by the National Surgical Adjuvant Breast & Bowel Project (NSABP), which strongly advocates excision plus radiation therapy for all patients with DCIS who elect to preserve their breast. This is a recommendation that Dr. Silverstein and colleagues on the study consider too broad at this time. "It is like treating every patient with an infection with antibiotics-it simply isn't necessary," says Silverstein.

"In defense of the NSABP, its trial was designed more than 14 years ago," says Silverstein. "At that time researchers were asking a single broad question: Does radiation therapy benefit patients with ductal carcinoma in situ treated with breast preservation? The answer to that question is clearly, yes. However, the NSABP study was not designed to answer the more sophisticated and discriminating questions we ask today of exactly which subgroups might benefit from radiotherapy and by how much. If the benefit in a given subgroup is small, the advantage gained by radiation therapy will probably be more than offset by its cost and side effects."

According to Silverstein, radiotherapy is expensive (at times in excess of $15,000) and, in some cases, is accompanied by side effects. Radiation fibrosis is the most common side effect, particularly with some of the older outmoded radiotherapy techniques common during the 1980s. This complication changes the texture of the breast, makes mammographic follow up more difficult, and may result in delayed diagnosis if there is a recurrence. Additionally, radiation therapy makes skin-sparing mastectomy more difficult or sometimes impossible, if required later.

Doctors must weigh the benefits of radiation therapy, in terms of decrease in local recurrence, against the side effects, complications, inconvenience, and costs of radiation therapy. Silverstein argues that for many women the small or non-existant benefits are not worth the drawbacks and urges all patients with DCIS considering radiation therapy to seek a second opinion.

In an attempt to achieve sufficiently wide margins, closely integrated teamwork is key says Silverstein. To achieve this, breast cancer surgery is best performed by an integrated, experienced team of surgeon, pathologist and radiologist - with long-term follow-up by a team consisting of radiologist, surgical and medical oncologist.

More than 90 percent of DCIS is found by mammography. It's nether palpable nor visible in the operating room. In other words, the surgeon can't feel it or see it. "The initial excision offers the best chance to remove the cancer with adequate margins while achieving the best possible cosmetic result. At USC we use multiple guide wires in surgeries to localize all DCIS lesions followed by complete and sequential tissue processing," says Silverstein. "It's very difficult to remove a DCIS and achieve an adequate margin using a single wire, which is the current standard throughout the U.S."

"The balance between adequate margins and a good cosmetic result is a difficult one to achieve," says Silverstein. "Although most of these technologies are available in the community they are not often well integrated. For now, the best treatment options lies with specialized multidisciplinary breast centers. They have the all the resources - in terms of skilled radiologists, surgeons, and pathologists, working as an integrated team."

"The current paradigm requires radiation therapy for all patients with DCIS who elect breast preservation," concludes Silverstein. "This paper may change such thinking - in that it allows clinicians to identify patients for whom there will be little or no benefit from radiation therapy."
-end-
Editor's notes:
Other co-authors of the study "Margin Width: A Critical Determinant of Local Control in Patients with Ductal Carcinoma in Situ of the Breast" include: Michael D. Lagios, M.D. (St. Mary's Hospital, San Francisco, Calif.), Susan Groshen, Ph.D., James R. Waisman, M.D., (USC/Norris) Bernard S. Lewinsky, M.D., Silvana Martino, D.O., Parvis Gamagami, M.D. and William J. Colburn, M.D. (The Breast Center, Van Nuys, Calif.)

A website on the study will be posted on Wednesday, May 12 at 2 p.m. Pacific Time at: www.usc.edu/go/breastcancer.



University of Southern California

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.